

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6540310

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THOMAS E. ICHIM	02/06/2021
TIMOTHY G. DIXON	02/06/2021
RECEIVING PARTY DATA	
Name:	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Street Address:	4093 OCEANSIDE BLVD, SUITE B
City:	OCEANSIDE
State/Country:	CALIFORNIA
Postal Code:	92056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16866430
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5035463452
Email:	marc@bapalaw.com
Correspondent Name:	MARC BAUMGARTNER
Address Line 1:	2900 NW CLEARWATER DR
Address Line 2:	STE 200
Address Line 4:	BEND, OREGON 97703
NAME OF SUBMITTER:	MARC BAUMGARTNER
SIGNATURE:	/Marc Baumgartner/
DATE SIGNED:	02/08/2021
Total Attachments: 2	
source=Exe_TSI_ASGN_430#page1.tif	
source=Exe_TSI_ASGN_430#page2.tif	

ASSIGNMENT OF INVENTION AND PATENT APPLICATION

Whereas, (1) I, Thomas E. Ichim, an individual having a mailing address in Oceanside, California, and (2) I, Timothy G. Dixon, an individual having a mailing address in Oceanside California, herein referred to collectively as "ASSIGNORS", have invented new and useful innovations described in U.S. Non-Provisional Application Serial No. 16/866,430, titled "Nutraceuticals for the Prevention, Inhibition, and Treatment of SARS-Cov-2 and Associated COVID-19", filed on April 4th, 2020;

herein referred to collectively as the "Invention".

And Whereas, Therapeutic Solutions International, Inc., with its principal place of business at 4093 Oceanside Blvd., Suite B, Oceanside, CA 92056, herein referred to as ASSIGNEE, desires to acquire the entire right, title, and interest in and to the said Invention,

Now therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNORS hereby acknowledge that they have sold, assigned, transferred, and set over, and by these presents do hereby sell, assign, and transfer, and set over unto ASSIGNEE and its successors and assigns, 100% of the following:

- (A) ASSIGNORS right, title and interest in and to the Invention described in U.S. Non-Provisional Application Serial No. 16/866,430;
- (B) any patent or reissues that claim priority to the Invention described in U.S. Non-Provisional Application Serial No. 16/866,430;
- (C) any continuations, continuations-in-part, substitutes, or divisionals that claim priority to the Invention described in U.S. Non-Provisional Application Serial No. 16/866,430;

ASSIGNORS authorize and request the Commissioner for Patents to issue any resulting patent(s) as follows: 0% to ASSIGNORS and 100% to ASSIGNEE.

ASSIGNORS hereby further sell, assign, transfer and set over unto ASSIGNEE, 100% of ASSIGNORS' entire right, title, and interest in and to said Invention in the United States and every country foreign to the United States. ASSIGNORS agrees to execute all papers, give any required testimony, and perform other lawful acts, at ASSIGNEE'S expense, as ASSIGNEE may require to enable ASSIGNEE to perfect ASSIGNEE'S

